{"id":"lipocol-and-mevacor","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Myalgia (muscle pain)"},{"rate":"1-3%","effect":"Elevated liver enzymes"},{"rate":"<0.1%","effect":"Rhabdomyolysis"},{"rate":"1-2%","effect":"Headache"},{"rate":"1-3%","effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs block the enzyme HMG-CoA reductase, which catalyzes an early and rate-limiting step in cholesterol biosynthesis. By reducing hepatic cholesterol production, they lower LDL cholesterol levels in the blood and reduce cardiovascular risk. Mevacor (lovastatin) is a naturally derived statin, while LipoCol typically refers to a lovastatin-based formulation.","oneSentence":"LipoCol and Mevacor are statins that inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:33.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Primary prevention of coronary heart disease"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT01269762","phase":"PHASE4","title":"Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2011-01","conditions":"Healthy Volunteer","enrollment":14},{"nctId":"NCT01346670","phase":"PHASE4","title":"Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2006-10","conditions":"Healthy Volunteer","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LipoCol and Mevacor","genericName":"LipoCol and Mevacor","companyName":"Taipei Medical University WanFang Hospital","companyId":"taipei-medical-university-wanfang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LipoCol and Mevacor are statins that inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver. Used for Hypercholesterolemia, Primary prevention of coronary heart disease, Secondary prevention of cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}